Company intelligence / Profile preview

KeraLink International

Baltimore, Maryland, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

KeraLink International’s programs are preclinical, aiming to restore sight by developing scalable bioengineered implants, innovative diagnostics, and non-pharmaceutical treatments for corneal blindness, primarily targeting underserved populations. No clinical data yet because programs are in development/innovation phase.

Therapeutic areas: Infectious DiseasesOphthalmology
Modalities: Bio-engineered corneal implantDeviceNon-pharmaceutical antimicrobial
Industry: Therapeutic Medical Devices

Partnerships

Ultralight Labs (software platform for medical device documentation/compliance)Local NGOs and academic/clinical partners (for workforce training/eye care program delivery)

Beyond the preview

Go deeper on KeraLink International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KeraLink International.

Explore the full profile